These Were the Five Best and Worst Performing Healthcare Stocks in Q3 202224/7 Wall Street • 10/25/22
Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing LossGlobeNewsWire • 10/13/22
Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with TinnitusGlobeNewsWire • 08/01/22
Otonomy, Inc. (OTIC) CEO Dave Weber on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 07/26/22
Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 07/25/22
Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate UpdateGlobeNewsWire • 07/18/22
Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual MeetingGlobeNewsWire • 05/12/22
Otonomy, Inc. (OTIC) CEO Dr. David Weber on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/10/22
Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/09/22
Otonomy to Report First Quarter 2022 Financial Results and Provide Corporate UpdateGlobeNewsWire • 05/02/22
Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing LossGlobeNewsWire • 04/20/22
Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 02/28/22
Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in TinnitusGlobeNewsWire • 02/22/22
Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate UpdateGlobeNewsWire • 02/17/22
Otonomy Announces OTO-413 Presentations at American Auditory Society Annual MeetingGlobeNewsWire • 02/16/22